Business Wire

Tempo Acquires ALM Works to Deliver Integrated Strategic Portfolio Management Offering

22.12.2021 20:17:00 EET | Business Wire | Press release

Share

Tempo Software, the leader in team time management and productivity-enhancing solutions, today announced the acquisition of ALM Works, developer of the Structure for Jira software suite that enables project and program managers to make better decisions, work more efficiently, and deliver predictable results. A top-selling project management solution, ALM Works helps over 5000 organizations worldwide visualize, track and manage progress across large-scale, complex projects. Tempo and ALM Works together will provide the first suite of purpose-built program management apps to meet project, program and portfolio management needs for over 70 million users within the Atlassian Ecosystem.

The combination of Tempo’s team time and capacity management solutions and ALM Works’ project and artifact structuring solutions will enable program managers to easily understand whether key initiatives are on track and meeting strategic objectives. A recent Tempo survey showed that 55% of software development executives reported that they use time tracking insights to inform project and portfolio management. This new combination of Tempo and ALM Works will provide organizations with the visibility required to move between strategy and daily execution, make informed decisions, and share progress with executives and stakeholders.

“For over a decade, ALM Works has set themselves apart within the Atlassian Ecosystem due to their focused efforts on helping bring structure to complex project data,” said Mark Lorion, CEO, Tempo Software. “Through an even tighter integration with ALM Works, we are excited to bring a modern, easy-to-use and scalable program management solution to market and to our many shared customers and partners. Together we will uniquely support the teams who operate within Jira on a daily basis and provide the data that senior leadership teams need to be responsive as they set product strategy for an organization.”

“ALM Works focuses on enabling project and program managers to solve complex problems with our flexible, adaptable Structure solution,” said Igor Sereda, ALM Works CEO. “By bringing ALM Works together with Tempo’s industry-leading time tracking and productivity management suite of products, we’re now well-positioned to deliver the most comprehensive program and portfolio management offering to the market. I am proud of the work our team has accomplished over the past 17 years and look forward to bringing visibility and strategic insights to even more people and teams.”

Combined with the recent acquisition of Roadmunk, the addition of ALM Works strengthens Tempo’s strategic portfolio management offering. As a modern and integrated solution suite, Tempo will meet the growing needs of today’s distributed and complex product organizations who need to project, plan, and adapt based on timely organizational capacity data and insights.

Supporting Resources:

About Tempo
Tempo Software offers integrated applications for time management, resource planning, and budget management for software engineering and product management teams. Our customers gain an unrivaled understanding of time and effort, and they improve how their teams plan and manage their work. This provides an aligned understanding of and plan for how time –the most precious, and finite resource–is optimized. Tempo Software is seamlessly integrated across popular DevOps tools and a natural and automated part of users’ workflows.

Headquartered in Boston and with offices in Reykjavik, Iceland and Montreal, Canada, Tempo Software is one of the largest and most successful companies in the Atlassian ecosystem.

Tempo has more than 20,000 customers across a range of industries in more than 100 countries. It works with hundreds of partners around the world, offering resale, training, and consultancy in local languages. Tempo is available in English, French, German, Spanish, Portuguese, and Russian, with Japanese coming soon. To learn more about Tempo, visit www.tempo.io

About ALM Works
ALM Works provides software products to empower project managers around the world with visibility and control. ALM Works’ flagship product, Structure for Jira, is a project and portfolio management tool for Atlassian, used by thousands of customers in over 100 countries. Structure, together with its extensions such as Structure.Gantt, is made for project managers and other people responsible for planning, tracking, and getting things done at an organization. It allows them to work efficiently, deliver predictable results, see problems earlier, make better decisions and communicate with clarity and confidence to their teams, managers and clients.

ALM Works is headquartered in Boston with offices in Saint-Petersburg, Russia. To learn more about ALM Works, visit almworks.com.

About Diversis Capital, L.P.
Founded in 2013, Diversis is a software and technology focused private equity fund with $1bn+ in AUM that invests in lower middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its Operating Partners and Strategic Advisors work alongside management teams to help build successful organizations positioned for long-term growth. To learn more, visit www.diversis.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Escalate PR for Tempo.io
tempo@escalatepr.com

Joel Richman
joel@escalatepr.com
+1 617 312 5942

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye